0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.

Int J Mol Sci · 2022 · PMC9820614 · PMID 36613994

Europe PMC DOI

hedged sentences

0.0829

closest p · 1.7× alpha

0.0829

boldest claim

The sentences

near significancep = 0.0829so close (0.05 < p ≤ 0.1)

Additionally, time to complete healing tended to be faster for study eyes treated with RGN-259 than those eyes treated with placebo with near significance ( p = 0.0829, Kaplan–Meier analysis).

also in 505 other papers

showed a trendp = 0.0829so close (0.05 < p ≤ 0.1)

Time to complete healing also showed a trend towards efficacy ( p = 0.0829, Kaplan–Meier) with 0.1% RGN-259.

also in 53,322 other papers

a strong trendno p-value reported

Despite these limitations, the data showed a strong trend for healing and significant findings for the subjects in many important parameters, indicating that RGN-259 was fast acting and has the potential to yield clinically meaningful findings in a larger patient population.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.